This negotiation case is meant to be used in conjunction with "Eli Lilly and Company" (F-0794); half the class works from one case and half from the other. Lilly is considering acquiring Hybritech, but the genetic-engineering company's future cash flows are difficult to predict and value. Both companies want to effect the merger, but the cases, which provide essentially the same information in all other respects, provide widely divergent projected cash flows. (The B case is F-0793.)
